You are here
Consultations
We consult on proposed changes to the way we regulate medicines, medical devices and biologicals. Additional consultations about changes to the Poisons Standard can be found in the Scheduling decisions (interim) section of our publications hub.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Scheduling (national classification system) (69)
- Medical devices (63)
- Therapeutic goods regulation (14)
- Over the counter medicine (12)
- Prescription medicines (10)
- Complementary medicines (9)
- Medicines (9)
- Advisory bodies and committees (7)
- Legislation (6)
- Manufacturing (5)
- Biologicals (4)
- Labelling and packaging (4)
- Listed medicines (4)
- Non-prescription medicines (4)
- Advertising (3)
- Fees and payments (2)
- Sunscreens (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Clinical trials (1)
- Import and export (1)
- In Vitro Diagnostic medical devices (IVDs) (1)
- Medical devices safety (1)
- Medicinal cannabis hub (1)
- Medicines safety (1)
- Nicotine vaping products hub (1)
- Other therapeutic goods (1)
- Safety (1)
- Unique Device Identification (UDI) hub (1)
More on consultations
Find more scheduling consultations on the Poisons Standard in our Interim decisions.
Read the details of recent consultations, submissions and decisions at the TGA Consultation hub.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Results for
"[search-keyword]"
Search
218 result(s) found, displaying 51 to 75
- Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS, Joint ACMS-ACCS, November 2021Closed onConsultationThis consultation is for interim decisions made in relation to applications to amend the Poisons Standard, following advice sought at the 3-4 November 2021 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
- Public consultation on interim decisions to amend the Poisons Standard (isothiazolinones) - Joint ACMS-ACCS, June 2020Closed onConsultationThis consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 23-25 June 2020 meetings of the Advisory Committee on Medicines Scheduling (ACMS).
- Public consultation on interim decisions to amend the Poisons Standard (isothiazolinones) - Joint ACMS-ACCS, June 2020Closed onConsultationThis consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 23-25 June 2020 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
- Consultation: Proposed refinements to the regulation of medical devices that are substances introduced into the human body via a body orifice or applied to the skinClosed onConsultationSubmissions published and summarised as part of a consultation on medical devices that are substances for introduction into the body.
- Consultation: Building a more robust medicine supply - proposals to help prevent, mitigate and manage medicine shortagesClosed onConsultationView the outcomes of public consultation on building a more robust medicine supply
- Consultation: Proposed update to the evidence guidelines for listed medicinesClosed onConsultationThe TGA is seeking feedback on the updated 'Listed medicines evidence guidelines - How to demonstrate efficacy of listed medicines'. Closing date: 1 April 2022
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): TriptansClosed onConsultationOutcomes of the consultation and submissions received have now been published
- Consultation: Remaking of standards and legislative instruments for human cell and tissue (HCT) products, blood and blood componentsClosed onConsultationThe TGA is seeking feedback on a proposal to remake some of the legislative instruments relating to human cell and tissue (HCT) products (including blood and blood components), which sunset in October 2021. Closing date: 11 July 2021
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)Closed onConsultationOutcomes of the consultation and submissions received have now been published
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): MentholClosed onConsultationOutcomes of the consultation and submissions received have now been published
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylateClosed onConsultationThe TGA is seeking feedback on proposed advisory statements for OTC medicines containing methyl salicylate for inclusion in RASML. Closing date: 18 May 2021
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistaminesClosed onConsultationOutcomes of the consultation and submissions received have now been published
- Consultation: Proposed improvements to the Therapeutic Goods Advertising CodeClosed onConsultationThe outcomes of the public consultation into proposed improvements to the Therapeutic Goods Advertising Code have been published.
- Consultation: Proposed refinements to the regulation of personalised medical devicesClosed onConsultationThe closing date has been extended and now closes on 14 July
- Consultation: Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirementClosed onConsultationA further update by the TGA on the proposed reforms to medicinal cannabis, labelling and packaging requirements.
- Consultation: Proposed amendments to the Poisons Standard - Joint ACMS/ACCS #28, June 2021Closed onConsultationProposed amendments to the Poisons Standard, including substances in hand sanitisers. Closing date: 27 May 2021
- Consultation: Proposed amendments to the Poisons Standard - ACCS #31, June 2021Closed onConsultationProposed amendments to the Poisons Standard. Closing date: 4 June 2021
- Consultation: Australian Medical Device Regulations definition of Central Circulatory System (CCS)Closed onConsultationA submission summary on the Australian Regulations definition of CCS consultation is available on our consultation hub
- Consultation: Proposed amendments to the Poisons Standard (sodium nitrite) - Joint ACMS/ACCS #28, June 2021Closed onConsultationThe closing date for this consultation has been extended until 27 May 2021
- Consultation: Proposed amendments to the Poisons Standard - ACMS #34, June 2021Closed onConsultationProposed amendments to the Poisons Standard. Closing date: 27 May 2021
- Consultation: Proposed amendments to the Poisons Standard (oral contraceptives) - ACMS #34, June 2021Closed onConsultationProposed amendments to the Poisons Standard. Closing date: 27 May 2021
- Impact of amendments to the application process for inclusion of Class I medical devices in the Australian Register of Therapeutic Goods (ARTG)Closed onConsultationThe Australian Government is undertaking a significant program to reform the regulation of therapeutic goods in Australia. As part of the Australian Government Department of Health, the Therapeutic Goods Administration (TGA) regulates therapeutic goods, and is responsible for implementing the Government’s reforms. The TGA has issued this survey as part of the Government’s reform program.
- IMDRF consultation: Assessment and Decision Process for the Recognition of a Conformity Assessment Body Conducting Medical Device Regulatory ReviewsClosed onConsultationThe IMDRF working group is seeking comments from interested parties on the proposed guidance document. Closing date: 19 April 2021
- Consultation: Repurposing of prescription medicinesClosed onConsultationThe closing date has been extended until 30 March 2021.
- Consultation: Proposed regulatory options for medical devices containing nanomaterialsClosed onConsultationTGA is seeking comments on whether the Australian medical device regulatory framework should be aligned to the EU framework for medical devices containing nanomaterials. Closing date: 9 April 2021